Suppr超能文献

一种豚鼠适应株苏丹病毒的研制与特性分析

Development and Characterization of a Guinea Pig-Adapted Sudan Virus.

作者信息

Wong Gary, He Shihua, Wei Haiyan, Kroeker Andrea, Audet Jonathan, Leung Anders, Cutts Todd, Graham Jill, Kobasa Darwyn, Embury-Hyatt Carissa, Kobinger Gary P, Qiu Xiangguo

机构信息

Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada.

Special Pathogens Program, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada.

出版信息

J Virol. 2015 Oct 21;90(1):392-9. doi: 10.1128/JVI.02331-15. Print 2016 Jan 1.

Abstract

UNLABELLED

Infections with Sudan virus (SUDV), a member of the genus Ebolavirus, result in a severe hemorrhagic fever with a fatal outcome in over 50% of human cases. The paucity of prophylactics and therapeutics against SUDV is attributed to the lack of a small-animal model to screen promising compounds. By repeatedly passaging SUDV within the livers and spleens of guinea pigs in vivo, a guinea pig-adapted SUDV variant (SUDV-GA) uniformly lethal to these animals, with a 50% lethal dose (LD50) of 5.3 × 10(-2) 50% tissue culture infective doses (TCID50), was developed. Animals infected with SUDV-GA developed high viremia and died between 9 and 14 days postinfection. Several hallmarks of SUDV infection, including lymphadenopathy, increased liver enzyme activities, and coagulation abnormalities, were observed. Virological analyses and gross pathology, histopathology, and immunohistochemistry findings indicate that SUDV-GA replicates in the livers and spleens of infected animals similarly to SUDV infections in nonhuman primates. These developments will accelerate the development of specific medical countermeasures in preparation for a future disease outbreak due to SUDV.

IMPORTANCE

A disease outbreak due to Ebola virus (EBOV), suspected to have emerged during December 2013 in Guinea, with over 11,000 dead and 28,000 infected, is finally winding down. Experimental EBOV vaccines and treatments were administered to patients under compassionate circumstances with promising results, and availability of an approved countermeasure appears to be close. However, the same range of experimental candidates against a potential disease outbreak caused by other members of the genus Ebolavirus, such as Sudan virus (SUDV), is not readily available. One bottleneck contributing to this situation is the lack of a small-animal model to screen promising drugs in an efficient and economical manner. To address this, we have generated a SUDV variant (SUDV-GA) that is uniformly lethal to guinea pigs. Animals infected with SUDV-GA develop disease similar to that of SUDV-infected humans and monkeys. We believe that this model will significantly accelerate the development of life-saving measures against SUDV infections.

摘要

未标记

苏丹病毒(SUDV)是埃博拉病毒属的成员,其感染会导致严重出血热,在超过50%的人类病例中会导致致命后果。针对SUDV的预防和治疗药物匮乏,原因是缺乏用于筛选有前景化合物的小动物模型。通过在豚鼠的肝脏和脾脏内反复传代SUDV,开发出了一种适应豚鼠的SUDV变体(SUDV-GA),该变体对这些动物具有一致的致死性,半数致死剂量(LD50)为5.3×10⁻² 50%组织培养感染剂量(TCID50)。感染SUDV-GA的动物出现高病毒血症,并在感染后9至14天死亡。观察到了SUDV感染的几个特征,包括淋巴结病、肝酶活性增加和凝血异常。病毒学分析以及大体病理学、组织病理学和免疫组织化学结果表明,SUDV-GA在受感染动物的肝脏和脾脏中的复制情况与在非人类灵长类动物中的SUDV感染相似。这些进展将加速针对未来因SUDV引发疾病爆发的特定医学对策的开发。

重要性

2013年12月疑似在几内亚出现的埃博拉病毒(EBOV)疫情最终逐渐平息,此次疫情导致超过11000人死亡,28000人感染。在同情性情况下向患者施用了实验性EBOV疫苗和治疗方法,取得了有前景的结果,并且一种获批的对策似乎即将问世。然而,针对由埃博拉病毒属其他成员(如苏丹病毒(SUDV))引发的潜在疾病爆发的同类实验候选药物并不容易获得。造成这种情况的一个瓶颈是缺乏一种以高效且经济的方式筛选有前景药物的小动物模型。为解决这一问题,我们培育出了一种对豚鼠具有一致致死性的SUDV变体(SUDV-GA)。感染SUDV-GA的动物所患疾病与感染SUDV的人类和猴子相似。我们相信,这个模型将显著加速针对SUDV感染的救命措施的开发。

相似文献

1
Development and Characterization of a Guinea Pig-Adapted Sudan Virus.
J Virol. 2015 Oct 21;90(1):392-9. doi: 10.1128/JVI.02331-15. Print 2016 Jan 1.
2
Characterization of Sudan Ebolavirus infection in ferrets.
Oncotarget. 2017 Jul 11;8(28):46262-46272. doi: 10.18632/oncotarget.17694.
3
Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus.
J Virol. 2014 Nov;88(21):12703-14. doi: 10.1128/JVI.01643-14. Epub 2014 Aug 20.
4
Interferon α/β Receptor-Deficient Mice as a Model for Ebola Virus Disease.
J Infect Dis. 2015 Oct 1;212 Suppl 2:S282-94. doi: 10.1093/infdis/jiv215. Epub 2015 May 4.
5
Natural history of infection in rhesus and cynomolgus macaques.
Emerg Microbes Infect. 2022 Dec;11(1):1635-1646. doi: 10.1080/22221751.2022.2086072.
6
STAT-1 Knockout Mice as a Model for Wild-Type Sudan Virus (SUDV).
Viruses. 2021 Jul 17;13(7):1388. doi: 10.3390/v13071388.
8
Experimental aerosolized guinea pig-adapted Zaire ebolavirus (variant: Mayinga) causes lethal pneumonia in guinea pigs.
Vet Pathol. 2015 Jan;52(1):21-5. doi: 10.1177/0300985814535612. Epub 2014 May 14.
10
A Two-Antibody Pan-Ebolavirus Cocktail Confers Broad Therapeutic Protection in Ferrets and Nonhuman Primates.
Cell Host Microbe. 2019 Jan 9;25(1):49-58.e5. doi: 10.1016/j.chom.2018.12.005.

引用本文的文献

1
2
Single-dose replicon RNA Sudan virus vaccine uniformly protects female guinea pigs from disease.
Nat Commun. 2025 May 6;16(1):4199. doi: 10.1038/s41467-025-59560-1.
3
Deep sequencing of serially passaged Sudan virus in guinea pigs uncovers adaptive mutations.
Heliyon. 2025 Jan 28;11(3):e42322. doi: 10.1016/j.heliyon.2025.e42322. eCollection 2025 Feb 15.
4
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.
Signal Transduct Target Ther. 2024 Sep 11;9(1):223. doi: 10.1038/s41392-024-01917-x.
5
Filoviruses: Scientific Gaps and Prototype Pathogen Recommendation.
J Infect Dis. 2023 Oct 18;228(Suppl 6):S446-S459. doi: 10.1093/infdis/jiad362.
6
A Single-Dose Intranasal Combination Panebolavirus Vaccine.
J Infect Dis. 2023 Nov 13;228(Suppl 7):S648-S659. doi: 10.1093/infdis/jiad266.
7
The rVSV-EBOV vaccine provides limited cross-protection against Sudan virus in guinea pigs.
NPJ Vaccines. 2023 Jun 10;8(1):91. doi: 10.1038/s41541-023-00685-z.
8
Animal Model Alternatives in Filovirus and Bornavirus Research.
Viruses. 2023 Jan 4;15(1):158. doi: 10.3390/v15010158.
10
Macrophage infection, activation, and histopathological findings in ebolavirus infection.
Front Cell Infect Microbiol. 2022 Oct 12;12:1023557. doi: 10.3389/fcimb.2022.1023557. eCollection 2022.

本文引用的文献

1
A Single-Vector, Single-Injection Trivalent Filovirus Vaccine: Proof of Concept Study in Outbred Guinea Pigs.
J Infect Dis. 2015 Oct 1;212 Suppl 2(Suppl 2):S384-8. doi: 10.1093/infdis/jiv126. Epub 2015 May 9.
2
Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles.
PLoS One. 2015 Mar 20;10(3):e0118881. doi: 10.1371/journal.pone.0118881. eCollection 2015.
4
5
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.
Nature. 2014 Oct 2;514(7520):47-53. doi: 10.1038/nature13777. Epub 2014 Aug 29.
6
Establishment and characterization of a lethal mouse model for the Angola strain of Marburg virus.
J Virol. 2014 Nov;88(21):12703-14. doi: 10.1128/JVI.01643-14. Epub 2014 Aug 20.
7
Synthetic antibodies with a human framework that protect mice from lethal Sudan ebolavirus challenge.
ACS Chem Biol. 2014 Oct 17;9(10):2263-73. doi: 10.1021/cb5006454. Epub 2014 Aug 26.
8
Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model.
Antiviral Res. 2014 May;105:17-21. doi: 10.1016/j.antiviral.2014.02.014. Epub 2014 Feb 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验